Rapid accumulation of virulent rift valley fever virus in mice from an attenuated virus carrying a single nucleotide substitution in the M RNA

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Morrill, John C ^a   Ikegami, Tetsuro ^a   Yoshikawa Iwata, Naoko ^a,b   Lokugamage, Nandadeva ^a   Won, Sungyong ^a,c   Terasaki, Kaori ^a   Zamoto Niikura, Aya ^a,b   Peters, C J ^a   Makino, Shinji ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GN PROTEIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; LIVE VACCINE; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BLOOD; BRAIN; CONTROLLED STUDY; GENOTYPE; KIDNEY; LIVER; MOUSE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; RIFT VALLEY FEVER BUNYAVIRUS; SEQUENCE ANALYSIS; SPLEEN; VIREMIA; VIRUS NEUTRALIZATION; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS VIRULENCE; ANIMAL; GENETICS; PATHOGENICITY; POINT MUTATION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRULENCE; VIRUS GENOME;

BUNYAVIRIDAE; MUS; PHLEBOVIRUS; RIFT VALLEY FEVER VIRUS; RNA VIRUSES;

ANIMALS; GENOME, VIRAL; MICE; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RIFT VALLEY FEVER VIRUS; RNA, VIRAL; VACCINES, ATTENUATED; VIRULENCE;

EID: 77956317429     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009986     Document Type: Article

References (48)

1. Schmaljohn C, Nichol ST (2007) Bunyaviruses. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin A, et al. (2007) Fields Virology, 5th ed. PhiladelphiaPA: Lippincott Williams and Wilkins. pp 1741-1789.
2. Balkhy HH, Memish ZA (2003) Rift Valley fever: an uninvited zoonosis in the Arabian peninsula. Int J Antimicrob Agents 21: 153-157.
3. Peters CJ, Meegan JM (1989) Rift Valley fever Beran G, ed. Boca RatonFla: CRC Press.
4. Meegan JM (1979) The Rift Valley fever epizootic in Egypt 1977-78. 1. Description of the epizootic and virological studies. Trans R Soc Trop Med Hyg 73: 618-623.
5. Morvan J, Rollin PE, Laventure S, Rakotoarivony I, Roux J (1992) Rift Valley fever epizootic in the central highlands of Madagascar. Res Virol 143: 407-415.
6. Shoemaker T, Boulianne C, Vincent MJ, Pezzanite L, Al-Qahtani MM, et al. (2002) Genetic analysis of viruses associated with emergence of Rift Valley fever in Saudi Arabia and Yemen, 2000-01. Emerg Infect Dis 8: 1415-1420.
7. CDC (2007) Rift Valley fever outbreak- Kenya, November 2006-January 2007. Morb Mortal Wkly Rep 56: 73-76.
8. Won S, Ikegami T, Peters CJ, Makino S (2007) NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J Virol 81: 13335-13345.
9. Le May N, Dubaele S, De Santis LP, Billecocq A, Bouloy M, et al. (2004) TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. Cell 116: 541-550, PMID: 14980221.
10. Le May N, Mansuroglu Z, Leger P, Josse T, Blot G, et al. (2008) A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells. PLoS Pathog 4: e13.
11. Ikegami T, Narayanan K, Won S, Kamitani W, Peters CJ, et al. (2009) Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog 5: e1000287.
12. Habjan M, Pichlmair A, Elliott RM, Overby AK, Glatter T, et al. (2009) NSs protein of Rift Valley Fever Virus induces the specific degradation of the doublestranded RNA-dependent protein kinase. J Virol 83: 4365-4375.
13. Saluzzo JF, Smith JF (1990) Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine. Vaccine 8: 369-375.
14. Muller R, Saluzzo JF, Lopez N, Dreier T, Turell M, et al. (1995) Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg 53: 405-411.
15. Vialat P, Billecocq A, Kohl A, Bouloy M (2000) The S segment of rift valley fever phlebovirus (Bunyaviridae) carries determinants for attenuation and virulence in mice. J Virol 74: 1538-1543.
16. Bird BH, Albarino CG, Hartman AL, Erickson BR, Ksiazek TG, et al. (2008) Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J Virol 82: 2681-2691.
17. Billecocq A, Gauliard N, Le May N, Elliott RM, Flick R, et al. (2008) RNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever viruses. Virology 378: 377-384.
18. Bird BH, Albarino CG, Nichol ST (2007) Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease. Virology 362: 10-15.
19. Bird BH, Khristova ML, Rollin PE, Ksiazek TG, Nichol ST (2007) Complete genome analysis of 33 ecologically and biologically diverse Rift Valley fever virus strains reveals widespread virus movement and low genetic diversity due to recent common ancestry. J Virol 81: 2805-2816.
20. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R (2006) Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439: 344-348.
21. Lee E, Hall RA, Lobigs M (2004) Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses. J Virol 78: 8271-8280.
22. Lee E, Lobigs M (2002) Mechanism of virulence attenuation of glycosaminoglycan- binding variants of Japanese encephalitis virus and Murray Valley encephalitis virus. J Virol 76: 4901-4911.
23. Lee E, Wright PJ, Davidson A, Lobigs M (2006) Virulence attenuation of Dengue virus due to augmented glycosaminoglycan-binding affinity and restriction in extraneural dissemination. J Gen Virol 87: 2791-2801.
24. Wang E, Brault AC, Powers AM, Kang W, Weaver SC (2003) Glycosaminoglycan binding properties of natural venezuelan equine encephalitis virus isolates. J Virol 77: 1204-1210.
25. Kroschewski H, Allison SL, Heinz FX, Mandl CW (2003) Role of heparin sulfate for attachment and entry of tick-borne encephalitis virus. Virology 308: 92-100.
26. Byrnes AP, Griffin DE (1998) Binding of Sindbis virus to cell surface heparin sulfate. J Virol 72: 7349-7356.
27. Caplen H, Peters CJ, Bishop DH (1985) Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 66 (Pt 10): 2271-2277.
28. Peters CJ, Anderson GW, Jr. (1981) Pathogenesis of Rift Valley fever. Contributions to Epidemiology & Biostatistics 3: 21-41.
29. Morrill JC, Mebus CA, Peters CJ (1997) Safety and efficacy of a mutagenattenuated Rift Valley fever virus vaccine in cattle. Am J Vet Res 58: 1104-1109.
30. Kilbourne ED, Easterday BC, McGregor S (1988) Evolution to predominance of swine influenza virus hemagglutinin mutants of predictable phenotype during single infections of the natural host. Proc Natl Acad Sci U S A 85: 8098-8101.
31. Sanz-Ramos M, Diaz-San Segundo F, Escarmis C, Domingo E, Sevilla N (2008) Hidden virulence determinants in a viral quasispecies in vivo. J Virol 82: 10465-10476.
32. Briones C, de Vicente A, Molina-Paris C, Domingo E (2006) Minority memory genomes can influence the evolution of HIV-1 quasispecies in vivo. Gene 384: 129-138.
33. Sironen T, Kallio ER, Vaheri A, Lundkvist A, Plyusnin A (2008) Quasispecies dynamics and fixation of a synonymous mutation in hantavirus transmission. J Gen Virol 89: 1309-1313.
34. Schmaljohn CS, Parker MD, Ennis WH, Dalrymple JM, Collett MS, et al. (1989) Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology 170: 184-192.
35. Besselaar TG, Blackburn NK (1991) Topological mapping of antigenic sites on the Rift Valley fever virus envelope glycoproteins using monoclonal antibodies. Arch Virol 121: 111-124.
36. Spik K, Shurtleff A, McElroy AK, Guttieri MC, Hooper JW, et al. (2006) Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tickborne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 24: 4657-4666.
37. Anderson GW, Jr., Slone TW, Jr., Peters CJ (1987) Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats. Microb Pathog 2: 283-293.
38. Harrington DG, Lupton HW, Crabbs CL, Peters CJ, Reynolds JA, et al. (1980) Evaluation of a formalin-inactivated Rift Valley fever vaccine in sheep. Am J Vet Res 41: 1559-1564.
39. Niklasson BS, Meadors GF, Peters CJ (1984) Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters. Acta Pathol Microbiol Immunol Scand [C] 92: 197-200.
40. Peters CJ, Jones D, Trotter R, Donaldson J, White J, et al. (1988) Experimental Rift Valley fever in rhesus macaques. Arch Virol 99: 31-44.
41. Peters CJ, Reynolds JA, Slone TW, Jones DE, Stephen EL (1986) Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antiviral Res 6: 285-297.
42. Pittman PR, Liu CT, Cannon TL, Makuch RS, Mangiafico JA, et al. (1999) Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine 18: 181-189.
43. Keegan K, Collett MS (1986) Use of bacterial expression cloning to define the amino acid sequences of antigenic determinants on the G2 glycoprotein of Rift Valley fever virus. J Virol 58: 263-270.
44. Won A, Ikegami T, Peters CJ, Makino S (2007) NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J Virol 81: in press.
45. Ikegami T, Won S, Peters CJ, Makino S (2006) Rescue of infectious Rift Valley fever virus entirely from cDNA, analysis of virus lacking NSsgene, and expression of a foreign gene. J Virol 80: 2933-2940.
46. Ikegami T, Peters CJ, Makino S (2005) Rift Valley fever virus nonstructural protein NSs promotes viral RNA replication and transcription in a minigenome system. J Virol 79: 5606-5615.
47. Tseng CT, Huang C, Newman P, Wang N, Narayanan K, et al. (2007) Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor. J Virol 81: 1162-1173.
48. Won S, Ikegami T, Peters CJ, Makino S (2006) NSm and 78-kilodalton proteins of Rift Valley fever virus are nonessential for viral replication in cell culture. J Virol 80: 8274-8278.